
STATUS UPDATE:

- (A) APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY**
 - (B) ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN KAO KUN**
 - (C) UPDATES ON VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA**
 - (D) UPDATES TO SHAREHOLDERS ON OTHER CLAIM(S) AGAINST OUE LIPPO HEALTHCARE LIMITED**
-

1. INTRODUCTION

1.1. Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in:

- (a) the announcements of OUE Lippo Healthcare Limited (the "**Company**") between 3 May 2016 to 29 May 2020, in relation to, *inter alia*, the appointment of receivers over certain subsidiaries of the Company¹;
- (b) the announcements of the Company between 13 December 2017 to 29 April 2020 in relation to the arbitration and enforcement proceedings against David Lin Kao Kun ("**David Lin**")²; and
- (c) the announcements of the Company between 22 February 2017 to 30 December 2019 in relation to on-going litigation with Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理(上海)有限公司) ("**Weixin**")³.

¹ Please refer to the Company's announcements dated 3 May 2016, 6 May 2016, 8 July 2016, 8 August 2016, 15 August 2016, 16 September 2016, 13 October 2016, 21 October 2016, 14 November 2016, 24 November 2016, 15 December 2016, 13 January 2017, 11 March 2017, 29 April 2017, 17 May 2017, 16 June 2017, 29 June 2017, 13 July 2017, 22 August 2017, 28 September 2017, 25 October 2017, 22 November 2017, 28 December 2017, 24 January 2018, 28 February 2018, 27 March 2018, 30 April 2018, 28 May 2018, 26 June 2018, 2 July 2018, 26 July 2018, 27 August 2018, 27 September 2018, 29 October 2018, 30 November 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 15 September 2019, 30 September 2019, 30 October 2019, 29 November 2019, 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, 29 April 2020, 19 May 2020, and 29 May 2020.

² Please refer to the Company's announcements dated 13 December 2017, 11 January 2018, 17 January 2019, 29 January 2019, 28 February 2019, 28 March 2019, 12 April 2019, 29 April 2019, 31 May 2019, 26 June 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 30 October 2019, 3 November 2019, 29 November 2019, 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, 22 April 2020, 29 April 2020, and 29 May 2020.

³ Please refer to the Company's announcements dated 22 February 2017, 20 December 2017, 6 August 2018, 23 August 2018, 30 November 2018, 5 December 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 14 October 2019, 30 October 2019, 25 November 2019, 29 November 2019, 12 December 2019 and 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, and 29 May 2020.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

2. APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY

2.1. High Court Suit No. 441 of 2016

As announced previously on 30 August 2019, the trial of Suit 441 concluded on 23 August 2019. As announced previously on 31 January 2020, parties filed their respective closing submissions on 18 October 2019, and their respective reply submissions on 29 November 2019. As announced previously on 29 May 2020, the Court invited parties to file further submissions to address certain points of law.

On 22 June 2020, parties filed their respective further submissions.

2.2. High Court Originating Summons No. 1104 of 2018 and High Court Originating Summons No. 689 of 2019

As announced previously on 28 February 2020, the hearings of OS 1104 and OS 689 were fixed to be heard together on 19 to 20 May 2020. These hearings were subsequently vacated and the evidentiary hearing of OS 689 has been fixed on 29 June 2020.

2.3. Aathar's Voluntary Arrangement

As announced previously on 28 February 2020, Aathar obtained the Official Assignee's permission to proceed to appeal against the decision to revoke his third voluntary arrangement. The appeal was part-heard on 14 January 2020 and 21 February 2020.

As announced previously on 29 April 2020, the further hearing of the appeal which was re-fixed to 8 to 9 April 2020, was vacated.

The further hearing of the Appeal took place on 18 to 19 June 2020, with the Court reserving its judgment to be issued subsequently.

There are no material updates on the other proceedings with the Crest Entities.

3. ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN

There are no material updates on the arbitration and enforcement proceedings against David Lin.

4. VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA

4.1 Proceedings commenced by Health Kind International (Shanghai) Limited (上海医霖医院投资管理咨询有限公司) (also referred to as "Healthkind Investment Management Consulting Co. Ltd.") ("Health Kind Shanghai")

As announced previously on 5 December 2018, 29 January 2019, 31 May 2019, 28 June 2019 and 30 July 2019, Health Kind Shanghai, a subsidiary of the Company, commenced legal proceedings before the Shanghai No. 1 Intermediate Court against David Lin and Weixin, seeking the return of 100% of the shares in Wuxi New District Phoenix Hospital Co., Ltd (无锡新区凤凰医院有限责任公司) ("**Wuxi Co.**"). In these

proceedings, Health Kind Shanghai contends that David Lin breached his fiduciary duties in causing Health Kind Shanghai to enter into rescission agreements on 8 November 2013 to transfer away Health Kind Shanghai's shares in Wuxi Co. to Shanghai Yilin Medical Management Consulting Co., Ltd (上海医霖医疗管理咨询有限公司) ("**Shanghai Yilin**"), and thereafter caused Shanghai Yilin to transfer the same shares to Weixin.

As announced on 14 October 2019 and 30 October 2019, the Shanghai No. 1 Intermediate Court has dismissed Health Kind Shanghai's claim against David Lin and Weixin. On 22 October 2019, Health Kind Shanghai filed an appeal with the Shanghai Higher Court against the Shanghai No. 1 Intermediate Court's decision.

As announced on 29 May 2020, the Shanghai Higher Court has fixed a hearing date for the appeal on 18 June 2020.

On 18 June 2020, parties attended before the Shanghai Higher Court. Health Kind Shanghai sought a stay of the appeal, pending the conclusion of separate proceedings commenced by Weixin (which is under the control of Receivers and Managers) before the Shanghai Pudong Court against David Lin and Chiang Hui-Hua for an order that David Lin and Chiang Hui-Hua return, *inter alia*, Weixin's business license and company stamp on the basis that Chiang Hui-Hua is no longer the legal representative of Weixin (the "**Weixin Control Dispute**") and therefore cannot represent Weixin or authorize the attorney to represent Weixin in the appeal. The outcome of the Weixin Control Dispute will determine who can represent Weixin in the appeal. The Shanghai Higher Court has adjourned the hearing accordingly. It has not fixed the next hearing date for the appeal.

In the meantime, as announced on 5 December 2018, 29 January 2019, 14 October 2019 and 30 October 2019, 100% of the shares in Wuxi Co. (which has a registered capital of RMB 44,000,000) remains frozen by the Shanghai No. 1 Intermediate Court from 30 November 2018 to 29 November 2021.

4.2 Proceedings commenced by Weixin

As announced previously on 23 August 2018, Weixin commenced legal proceedings against Wuxi Yilin Real Estate Development Co Ltd (无锡医霖置业发展有限公司) ("**Wuxi Yilin Real Estate**") and Wuxi Co. to seek a declaration that the land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co. dated 15 January 2015 is void.

As announced on 25 November 2019, the Wuxi Xinwu District Court issued its judgment on 22 November 2019 wherein it dismissed Weixin's application and held that the land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co is legitimate and binding on all relevant parties. The Court also ordered Weixin to pay the Court's fees for the proceedings (the "**Wuxi Judgment**").

As announced on 12 December 2019, Weixin appealed against the Wuxi Judgment on 4 December 2019 to the Wuxi Intermediate Court.

Weixin (which is under the control of Receivers and Managers) had previously applied to withdraw the appeal. Prior to the hearing on 5 June 2020, Wuxi Yilin Real Estate sought a stay of the appeal, pending the conclusion of the Weixin Control Dispute. The outcome of the Weixin Control Dispute will determine who can represent Weixin in the

appeal. In view of the foregoing, the Wuxi Intermediate Court determined to stay the appeal pending the Weixin Control Dispute and issued a written ruling accordingly.

4.3 Proceedings commenced by Wuxi Yilin Real Estate against Wuxi Co

In 2018, Wuxi Yilin Real Estate commenced legal proceedings against Wuxi Co before the Wuxi Xinwu District Court for outstanding rental under a tenancy agreement dated 7 February 2015 in relation to the property at 20 Chang Jiang North Road and an equipment rental agreement dated 15 January 2015.

On 23 January 2020, the proceedings were withdrawn due to the internal Court timelines.

5. UPDATES TO SHAREHOLDERS ON OTHER CLAIM(S) AGAINST OUE LIPPO HEALTHCARE LIMITED

There are no material updates on the other claims against the Company.

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
30 June 2020

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).